Please turn JavaScript on

JUVE Patent

Subscribe to JUVE Patent’s news feed.

Click on “Follow” and decide if you want to get news from JUVE Patent via RSS, as email newsletter, via mobile or on your personal news page.

Subscription to JUVE Patent comes without risk as you can unsubscribe instantly at any time.

You can also filter the feed to your needs via topics and keywords so that you only receive the news from JUVE Patent which you are really interested in. Click on the blue “Filter” button below to get started.

Title: JUVE Patent

Is this your feed? Claim it!

Publisher:  Unclaimed!
Message frequency:  0.91 / day

Message History

Expectations were high from the start, and it’s fair to say that the UPC has met many of them. Case numbers have grown rapidly, and the European court has become the go-to venue for international companies and SMEs alike. With the increasing number of rulings, from the Court of Appeal especially, a body of case law is gradually taking shape. And is providing users with legal ...


Read full story

Kodak does not infringe FujiFilm’s EP 3 511 174 and can therefore continue to manufacture and sell its planographic and lithographic printing plates in Germany and the UK. This is the decision of the second panel of the Court of Appeal (case IDs:


Read full story

ToolGen is seeking a global licensing agreement with Vertex for the use of the world’s first genome-editing therapy, Casgevy. The Korean biotech company is now stepping up the pressure once again on Vertex and its commercial manufacturing partner, Lonza. It has filed two further lawsuits at the Unified Patent Court and the District Court The Hague.

At the UPC local div...


Read full story

It is the next stage of escalation in the long-running dispute between the Brazilian company Silimed and its German competitor Polytech.

It is the kind of decision that makes compliance departments sit up and take notice. Anyone who violates a court injunction “particularly grossly” risks not only a fine but also personal imprisonment as a managing director. The Munich...


Read full story

Tim Austen worked at Three New Square for 13 years. There, he developed a particular focus on cases related to the life sciences industry. The junior barrister regularly appears before the Intellectual Property Enterprise Court and the High Court. In the past, he has also argued cases before the Court of Appeal and the Supreme Court, including Warner-Lambert against Actavis. ...


Read full story